NPPB and hydrops fetalis: Our findings demonstrated that sacubitril-valsartan significantly improved and stabilized the cardiac function of CAPD patients with HFpEF, which is supported by clinical presentation and laboratory parameters, including strengthened exercise ability, fewer signs and symptoms of HF, and decreased NT-proBNP levels and heart rate.